compar model issu yesterday today guidanc larg line
expect tweak reflect attach model describ
chang annual ep estim
ep guid ep chang ep estim
gener beaten estim recent year although
quarterli estim adjust
sale sale guidanc slightli prior target
rais sale estim entir increas alloc
gross gross guidanc last-publish
estim increas estim state confer call would
expect signific improv year post
sg guid sg prior estim within
rang increas slightli
 guid prior estim within
rang increas slightli
oper margin reiter guidanc prior estim
increas state margin expans would mute
oper margin forecast
non-oper incom guid non-oper incom
prior estim low increas
tax rate guid tax rate prior estim
increas
pleas see page report import disclosur
newer product portfolio good growth prospect tap tandem hand
late-stag agent pois launch next year give us confid
above-averag sale ep growth prospect mani key franchis subject
competit manag shown abil success navig
challeng past estim ep compound-annual-growth-rate compar industri
averag dividend yield attract
verzenio breast cancer emgal
perform diabet busi
notabl trulic jardianc
data readout olumin atop
derm pegilodecakin lung
revenu growth leverag
ep growth
modest growth alimta
support keytruda/alimta
combo declin thereaft
one four less visibl pipelin
candid gener
margin expans sooner greater
alimta declin rapidli
margin expans delay reduc
compani global biopharmaceut compani incorpor
indiana march lilli fulli spun anim health busi elanco lead
product area diabet metabol diseas oncolog among other
compani data cowen compani
compani data cowen compani
productstrul europ lc ex europ lc ex europ lc ex europ lc ex world-wide share europ lc ex europ lc ex europ lc ex europ lc ex world-wide share cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
end market sale euro end market sale world-wide share end market sale euro end market sale world-wide share cowen
compani data cowen compani
growth productstrul us share novo inject oral semaglutid risktrul europ lc ex fx -australia europetrul eu emerg marketstrul qweek dose type diabet rewind cv data file higher dose phase psoriasi market share europ lc ex fx taltz eu mod/sever psoriasi taltz axspa radiograph approv non-radiograph file basaglar/abasria settlement w/sni allow launch strong uptakebasaglar/abasria europ lc ex fx basaglar/abasria market eubasaglar/abasria countri basaglar/abasria insulin glargin diabet lantu biosimilar expectedjardi us empa-reg cv outcom studi reflect labeljardi europ lc ex fx -australia europejardi eu empa-reg data file file jardiance/trajenta nda eujardi japanjardi emerg market approv chinajardi world-wide share inhibitor share gross profit w/bi reflect revenue incl glyxambi synjardi hf type diabet file ckd heart failur pverzenio mbcverzenio europ lc ex fx verzenio mbcverzenio mbcverzenio inhib mbc adjuv bc prostat cancer cyramza expect despit competit pressur io target agentscyramza europ lc ex fx -australia europecyramza nsclc cyramza uptak gastriccyramza emerg marketscyramza ramucirumab approv gastric lung file lung file egfr nsclcolumi europ lc ex fx olumi inhib ra atop derm sle alopecia areata w/incytradjenta market share patent expir europ lc ex fx -australia europetrajenta expir expir emerg marketstradjenta world-wide share inhibitor share gross profit bi reflect revenu cowen
compani data cowen compani
new drugsglucagon europ lc ex fx gucagon hypoglycemia intranas baqsimi approv launch spetmeb europ lc ex fx adcirca pulmonari arteri cgrp mab market episod chronic migrain cluster ha oral human ant-egfr approv squamou nsclc us migrain tx approv await schedul oral altern deliveri consid via colucid ret-fusion/activ ret-mut cancer lung/thyroid file loxo acq close phase ii data show strong efficaci ae concern phase readout filingultra rapid act file dm develop ulcer coliti phase psoriasi phase crohn diseas phase diagnost tau imag agent lung rcc melanoma solid tumor earlier devel pancreat deposit mab alzheim diseas phase iitgf beta kinas phase sever pain cancer pain oa pain clbp phase safeti data rais question phase iibtk select non-coval btk inhibitor b-cell leukemias/lymphoma pi/ii initi aka insulin deliveri phase iibas phase dermat phase alzheim diseas phase iiforteo expir biosimilar launch new modal anticipatedforteo europ lc ex fx -australia europeforteo expir biosimilar launch anticipatedforteo patent expir emerg marketsforteo hormon osteoporosi two year durat treatmenterbitux revenu erbitux sale full right close royalti europ lc ex fx -australia europeerbitux royalti report ou revenu key greater transpar drug solderbitux royalti royalti kgaa own asset due fulli paid licenseerbitux royalti cowen
compani data cowen compani
new drug continuedlartruvo soft tissu sarcoma announc studi fail confirm oslartruvo europ lc ex fx lartruvo phase ii pancreat cancer pdgf alpha mab withdrawn markettot growth new drug sale drugsalimta exp pedi extens vitamin supplement patent prevail appeal pto deni ipr vitamin supplement patent approv use keytruda nsclcalimta europ lc ex fx -australia europealimta exp vitamin supplement patent til eu upheld eu gener francealimta exp method-of-us patent emerg marketsalimta synthetas inhib mesothelioma nscl io/target agent impact nsclc usageciali launch day exclus end sell author genericciali europ lc ex fx -australia europeciali expir expir emerg marketsciali bphhumatrop europ lc ex fx -australia europehumatrop emerg marketshumatrop expir europ lc ex fx -australia canada europestrattera expir emerg marketsstrattera deficit hyperactivityzyprexa expir author gener sale book herezyprexa europ lc ex fx -australia europezyprexa expir expir gener launch emerg marketszyprexa cowen
compani data cowen compani
establish drug continuedeffi expir includ pedi exclus effient europ lc ex fx -australia europeeffi expir emerg marketseffi trilog medic mgd patient accoast pre-tx trigger drug elut stent miss endpointsprozac europ lc ex fx -australia europeprozac competitionprozac emerg marketsprozac expir multipl gener soldcymbalta europ lc ex fx -australia europecymbalta exclus expir gener launch mid patent expir emerg marketscymbalta pain gad fibromyalgia chronic paingemzar europ lc ex fx -australia europegemzar emerg marketsgemzar nsclc bladder breast ovarian gener evista expir multipl gener soldevista europ lc ex fx -australia europeevista expir expir emerg marketsevista breast cancer market eu pursu chf market foreign sale over-the-counter cowen
compani data cowen compani
oral cd outlicens dura antibiot focusinject divest china repres major salesoth inject antibiot market share sni biosimilar approv discount version target accesshumalog europ lc ex fx -australia europehumalog biosimilar approv eu emerg marketshumalog act insulin patent expir europ lc ex fx -australia europehumulin emerg marketshumulin patent protectionoth productsinsulin patent expir intern product beirsdorf german drug manuf establish drug drug sale new product cowen
compani data cowen compani
trajenta end market sale euro rate end market sale world-wide share inhibitor share gross profit bi reflect revenuejardi end market sale euro rate end market sale world-wide share inhibitor share gross profit w/bi reflect revenue incl glyxambi synjardi hf piii type diabet file ckd heart failur piii cowen
time frameev top-lin data chf outcom trial btki addit data phase i/ii trial cll mcl pam phase ii data parkinson dementiamirikizumabphas top-lin data psoriasisphas top-lin data uc induct olumiantphas data atop dermat two breez trial pegilodecakin ii data nsclc cypress ph trial ret thyroid cancerssolanezumabphas top line data inherit alzheim stirzepatideiniti phase cv outcom trial vs dulaglutid phase top-lin data first five trial trulicityful phase data altern dose erlotinibu /eu/jp approv egfr nsclc relay posit chmp dec penu approv approv episod cluster headachejardiance/tradjenta/metformin xr fdcu approv file atop dermatitisselpercatinib approv ret nsclc thyroid cancereu/jp file ret nsclc thyroid cancertrulicityu approv rewind cv datau approv altern dose insulinu /eu/jp approv file dose oa paintaltzu /eu/jp approv non-radiograph ax spaeu/jp approv asverzeniocn approv bc monarch plu corporatealimta patentu patent litig rule alt salt formgerman/japan appeal rule cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl diabet portfolio
success pipelin product especi ramucirumab dulaglutid success
deal patent litig patent expir pressur uncertainti strateg
direct could includ outlook dividend greater expect
competit diabet affect franchis macro factor lessen appeal
